How the pharma CEO views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity

Formed with Hummingbird assets, $187M, Callio brings trend to Singapore

Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global

Plus: Introducing this year’s China Summit, and what’s eating FDA’s advisory committees?

Shanghai biotech partners with stealthy Foresite newco Vignette to advance T cell engager for autoimmune disease

Back to School 2024: Can biotech write a more successful playbook for translating from target to product?

Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury

BioCentury’s roundup of translational innovations

Arthur Caplan assesses the impacts of the 2014 campaign to get Josh Hardy compassionate use 

Former Novo Nordisk CSO discusses what’s next for obesity, and the impact quantum computing may have on life sciences